Brief: APONTIS PHARMA And AstraZeneca Extend Strategic Sales Cooperation
08/03/2022 06:35
March 8 (Reuters) - APONTIS PHARMA AG APPHG.DE :
* SIGNIFICANT STRENGTHENING OF CO-MARKETING/CO-PROMOTION OF
MEDICINES BUSINESS AREA
* EXTENSION OF COOPERATION TO FULL YEAR 2022
* SUBJECT OF AGREEMENT IS SUPPORTING SALES ACTIVITIES FOR A
TRIPLE
THERAPY IN AREA OF RESPIRATORY DISEASES
* APONTIS PHARMA AND ASTRAZENECA EXTEND STRATEGIC SALES
COOPERATION
Source text for Eikon: ID:nEQ9rZj6ra
Further company coverage: APPHG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Apontis Pharma AG
See all newsBrief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
Brief: APONTIS PHARMA Q1 EBITDA EUR 1.3 Million
Brief: Apontis Pharma Says Zentiva AG Submits Formal Request To Carry Out A Merger
Brief: Zentiva Says Amendeds Offer To Acquire Each Outstanding Share Of Apontis Pharma In Cash By Waiving Condition Of A Minimum Acceptance
Brief: Apontis Pharma: Zentiva To Launch Voluntary Public Purchase Offer At EUR 10.00 Per Share